Laura Geraldino-Pardilla1, Cesare Russo1, Jeremy Sokolove2,3, William H Robinson2,3, Afshin Zartoshti1, Jenny Van Eyk4, Justyna Fert-Bober4, Joao Lima5, Jon T Giles1, Joan M Bathon1. 1. Department of Medicine, Columbia University, College of Physicians & Surgeons, New York, NY. 2. Department of Medicine, Stanford University School of Medicine, Stanford. 3. Department of Medicine, VA Palo Alto Health Care System, Palo Alto. 4. The Heart Institute and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA. 5. Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Abstract
Objective: High levels of ACPAs in RA are associated with more severe arthritis and worse prognosis. However, the role of ACPAs in mediating the increased risk of heart failure in RA remains undefined. We examined whether specific ACPAs were associated with subclinical left ventricular (LV) phenotypes that presage heart failure. Methods: Sera from RA patients without clinical cardiovascular disease were assayed for specific ACPAs using a custom Bio-Plex bead assay, and their cross-sectional associations with cardiac magnetic resonance-derived LV measures were evaluated. High ACPA level was defined as ⩾ 75th percentile. Findings were assessed in a second independent RA cohort with an expanded panel of ACPAs and LV measures assessed by 3D-echocardiography. Results: In cohort 1 (n = 76), higher levels of anti-citrullinated fibrinogen 41-60 and anti-citrullinated vimentin antibodies were associated with a 10 and 6% higher adjusted mean LV mass index (LVMI), respectively, compared with lower antibody levels (P < 0.05). In contrast, higher levels of anti-citrullinated biglycan 247-266 were associated with a 13% lower adjusted mean LVMI compared with lower levels (P < 0.001). In cohort 2 (n = 74), the association between ACPAs targeting citrullinated fibrinogen and citrullinated vimentin peptides or protein and LVMI was confirmed: higher anti-citrullinated fibrinogen 556-575 and anti-citrullinated vimentin 58-77 antibody levels were associated with a higher adjusted mean LVMI (19 and 15%, respectively; P < 0.05), but no association with biglycan was found. Conclusion: Higher levels of antibodies targeting citrullinated fibrinogen and vimentin peptides or protein were associated with a higher mean LVMI in both RA cohorts, potentially implicating autoimmune targeting of citrullinated proteins in myocardial remodelling in RA.
Objective: High levels of ACPAs in RA are associated with more severe arthritis and worse prognosis. However, the role of ACPAs in mediating the increased risk of heart failure in RA remains undefined. We examined whether specific ACPAs were associated with subclinical left ventricular (LV) phenotypes that presage heart failure. Methods: Sera from RApatients without clinical cardiovascular disease were assayed for specific ACPAs using a custom Bio-Plex bead assay, and their cross-sectional associations with cardiac magnetic resonance-derived LV measures were evaluated. High ACPA level was defined as ⩾ 75th percentile. Findings were assessed in a second independent RA cohort with an expanded panel of ACPAs and LV measures assessed by 3D-echocardiography. Results: In cohort 1 (n = 76), higher levels of anti-citrullinated fibrinogen 41-60 and anti-citrullinated vimentin antibodies were associated with a 10 and 6% higher adjusted mean LV mass index (LVMI), respectively, compared with lower antibody levels (P < 0.05). In contrast, higher levels of anti-citrullinated biglycan 247-266 were associated with a 13% lower adjusted mean LVMI compared with lower levels (P < 0.001). In cohort 2 (n = 74), the association between ACPAs targeting citrullinated fibrinogen and citrullinated vimentin peptides or protein and LVMI was confirmed: higher anti-citrullinated fibrinogen 556-575 and anti-citrullinated vimentin 58-77 antibody levels were associated with a higher adjusted mean LVMI (19 and 15%, respectively; P < 0.05), but no association with biglycan was found. Conclusion: Higher levels of antibodies targeting citrullinated fibrinogen and vimentin peptides or protein were associated with a higher mean LVMI in both RA cohorts, potentially implicating autoimmune targeting of citrullinated proteins in myocardial remodelling in RA.
Authors: E Blair Solow; Fang Yu; Geoffrey M Thiele; Jeremy Sokolove; William H Robinson; Zachary M Pruhs; Kaleb D Michaud; Alan R Erickson; Harlan Sayles; Gail S Kerr; Angelo L Gaffo; Liron Caplan; Lisa A Davis; Grant W Cannon; Andreas M Reimold; Joshua Baker; Pascale Schwab; Daniel R Anderson; Ted R Mikuls Journal: Rheumatology (Oxford) Date: 2015-04-07 Impact factor: 7.580
Authors: Jon T Giles; Ashkan A Malayeri; Veronica Fernandes; Wendy Post; Roger S Blumenthal; David Bluemke; Jens Vogel-Claussen; Moyses Szklo; Michelle Petri; Allan C Gelber; Lyndia Brumback; João Lima; Joan M Bathon Journal: Arthritis Rheum Date: 2010-04
Authors: Paulo J Nicola; Hilal Maradit-Kremers; Véronique L Roger; Steven J Jacobsen; Cynthia S Crowson; Karla V Ballman; Sherine E Gabriel Journal: Arthritis Rheum Date: 2005-02
Authors: Jon T Giles; Justyna Fert-Bober; Jin Kyun Park; Clifton O Bingham; Felipe Andrade; Karen Fox-Talbot; Dimitrios Pappas; Antony Rosen; Jennifer van Eyk; Joan M Bathon; Marc K Halushka Journal: Arthritis Res Ther Date: 2012-02-24 Impact factor: 5.156
Authors: Wolfgang Hueber; Beren H Tomooka; Franak Batliwalla; Wentian Li; Paul A Monach; Robert J Tibshirani; Ronald F Van Vollenhoven; Jon Lampa; Kazuyoshi Saito; Yoshiya Tanaka; Mark C Genovese; Lars Klareskog; Peter K Gregersen; William H Robinson Journal: Arthritis Res Ther Date: 2009-05-21 Impact factor: 5.156
Authors: Gilbert S Omenn; Lydie Lane; Christopher M Overall; Fernando J Corrales; Jochen M Schwenk; Young-Ki Paik; Jennifer E Van Eyk; Siqi Liu; Michael Snyder; Mark S Baker; Eric W Deutsch Journal: J Proteome Res Date: 2018-08-23 Impact factor: 4.466